Billie Bixby

Interests

Research

Thoracic oncology, early identification of lung cancer, advanced bronchoscopy, management of malignant and benign pleural disease.

Teaching

Pleural disease, thoracic oncology, complex airway disease, pulmonary procedures, bronchoscopy, critical care.

Courses

No activities entered.

Scholarly Contributions

Journals/Publications

• Kala, M., Weinkauf, C. C., Bixby, B. A., Nikolich-Žugich, J., Bhattacharya, D., LaFleur, B. J., Mosier, J. M., Parthasarathy, S., Bime, C., Erickson, H. E., Knox, K., Twigg, H. L., Wilson, R. C., Davidson, L., Castaneda, Y., Wong, R., Sonar, S. A., Coplen, C. P., Bhat, R., , Watanabe, M., et al. (2023).

  T-cell cellular stress and reticulocyte signatures, but not loss of naïve T lymphocytes, characterize severe COVID-19 in older adults

  . GeroScience. doi:10.1007/s11357-022-00724-y
  More info

  In children and younger adults up to 39 years of age, SARS-CoV-2 usually elicits mild symptoms that resemble the common cold. Disease severity increases with age starting at 30 and reaches astounding mortality rates that are ~330 fold higher in persons above 85 years of age compared to those 18–39 years old. To understand age-specific immune pathobiology of COVID-19, we have analyzed soluble mediators, cellular phenotypes, and transcriptome from over 80 COVID-19 patients of varying ages and disease severity, carefully controlling for age as a variable. We found that reticulocyte numbers and peripheral blood transcriptional signatures robustly correlated with disease severity. By contrast, decreased numbers and proportion of naïve T-cells, reported previously as a COVID-19 severity risk factor, were found to be general features of aging and not of COVID-19 severity, as they readily occurred in older participants experiencing only mild or no disease at all. Single-cell transcriptional signatures across age and severity groups showed that severe but not moderate/mild COVID-19 causes cell stress response in different T-cell populations, and some of that stress was unique to old severe participants, suggesting that in severe disease of older adults, these defenders of the organism may be disabled from performing immune protection. These findings shed new light on interactions between age and disease severity in COVID-19.
• , A. L., Lundgren, J. D., Grund, B., Barkauskas, C. E., Holland, T. L., Gottlieb, R. L., Sandkovsky, U., Brown, S. M., Knowlton, K. U., Self, W. H., Files, D. C., Jain, M. K., Benfield, T., Bowdish, M. E., Leshnower, B. G., Baker, J. V., Jensen, J. U., Gardner, E. M., Ginde, A. A., , Harris, E. S., et al. (2021). A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19. The New England journal of medicine, 384(10), 905-914.
  More info

  LY-CoV555, a neutralizing monoclonal antibody, has been associated with a decrease in viral load and the frequency of hospitalizations or emergency department visits among outpatients with coronavirus disease 2019 (Covid-19). Data are needed on the effect of this antibody in patients who are hospitalized with Covid-19.
• Harris, D. T., Badowski, M., Jernigan, B., Sprissler, R., Edwards, T., Cohen, R., Paul, S., Merchant, N., Weinkauf, C. C., Bime, C., Erickson, H. E., Bixby, B., Parthasarathy, S., Chaudhary, S., Natt, B., Cristan, E., El Aini, T., Rischard, F., Campion, J., , Chopra, M., et al. (2021). SARS-CoV-2 Rapid Antigen Testing of Symptomatic and Asymptomatic Individuals on the University of Arizona Campus. Biomedicines, 9(5).
  More info

  SARS-CoV-2, the cause of COVID19, has caused a pandemic that has infected more than 80 M and killed more than 1.6 M persons worldwide. In the US as of December 2020, it has infected more than 32 M people while causing more than 570,000 deaths. As the pandemic persists, there has been a public demand to reopen schools and university campuses. To consider these demands, it is necessary to rapidly identify those individuals infected with the virus and isolate them so that disease transmission can be stopped. In the present study, we examined the sensitivity of the Quidel Rapid Antigen test for use in screening both symptomatic and asymptomatic individuals at the University of Arizona from June to August 2020. A total of 885 symptomatic and 1551 asymptomatic subjects were assessed by antigen testing and real-time PCR testing. The sensitivity of the test for both symptomatic and asymptomatic persons was between 82 and 90%, with some caveats.
• Bixby, B. (2020). Core needle biopsy with endobronchial ultrasonography: single center experience with 100 cases. Journal of the American Society of Cytopathology.
• Bixby, B. (2018). Renal replacement therapy in patients with acute respiratory distress syndrome: a single-center retrospective study. International Journal of Nephrology and Renovascular Disease.

Proceedings Publications

• Bixby, B., & Upson, S. (2022).

  The Endobronchial Enigma

  . In American Thoracic Society.
• Bixby, B., & Upson, S. (2022).

  The Silent Solitary Fibrous Tumor

  . In American Thoracic Society.
• Bixby, B., Bixby, B., Sam, A., Sam, A., Scott, A., & Scott, A. (2022).

  A Rare Presentation of Disseminated Coccidioidomycosis Requiring Mechanical Intervention

  . In American Thoracic Society.
• Bixby, B., Khemasuwan, D., Shojaee, S., Balwan, A., Sanchez, T., Sorensen, J., & Reddy, C. (2021).

  Machine Learning Model to Predict Failure of Intrapleural tPA/DNase in Patients with Complicated Parapneumonic Effusions/Empyema: A Multicenter Study

  . In American Thoracic Society.